热门资讯> 正文
早些时候报道，Apellis获得FDA批准EMPAVELI治疗罕见肾病C3 G和IC-MPGN，蛋白尿减少68%
2025-07-29 15:32
- Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits
- Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
- Well-established safety profile, consistent across >2,200 patient years in approved indications
- C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
